Skip to main content
Journal cover image

Timing of Bronchoscopy and Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Host Pneumonia.

Journal articles  - Journal Article
Mourad, A; Lupu, DS; Richey, M; Steven, P; Fowler, VG; Perkins, B; Holland, TL; Bergin, SP
Published in: Open Forum Infect Dis
June 2026

BACKGROUND: Immunocompromised patients are at high risk of pneumonia, with associated poor outcomes. Rapid microbiologic diagnosis is crucial, yet diagnostic yields vary widely. We evaluated the variability in diagnostic yield of usual care testing and plasma microbial cell-free DNA (mcfDNA) sequencing in the prospective observational Pneumonia in the Immunocompromised-Use of the Karius Test for the Detection of Undiagnosed Pathogens (PICKUP) study, specifically focusing on timing of testing relative to the onset of pneumonia. METHODS: In this exploratory analysis, patient characteristics, variability in diagnostic yield, and the timing of bronchoscopy and mcfDNA sequencing from date of first abnormal imaging associated with suspected pneumonia were evaluated across enrolling sites. RESULTS: A total of 222 patients from 10 enrolling sites were analyzed. Usual care diagnostic yield varied across sites (range, 7.7%-57.7%). Patient characteristics did not differ between sites, and median time from abnormal imaging to bronchoscopy was not different across sites (3 days [IQR, 3]). Diagnostic yield of bronchoscopy was significantly higher when performed ≤3 days (early) from abnormal imaging (38.5% [52/135]) versus >3 days (delayed) (21.8% [19/87]) (difference, 16.7% [95% CI, 2.5%-28.3%]; P = .009). Adding mcfDNA sequencing to usual care testing increased overall diagnostic yield by 7.9% for patients undergoing early bronchoscopy, and by 16.3% for delayed bronchoscopy. CONCLUSIONS: Early bronchoscopy enhances diagnostic yield in immunocompromised patients with suspected pneumonia. Irrespective of timing, plasma mcfDNA sequencing increases overall diagnostic yield in this clinical scenario. These findings underscore the importance of prompt diagnostic strategies in this patient population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Open Forum Infect Dis

DOI

ISSN

2328-8957

Publication Date

June 2026

Volume

13

Issue

6

Start / End Page

ofag361

Location

United States

Related Subject Headings

  • 3207 Medical microbiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mourad, A., Lupu, D. S., Richey, M., Steven, P., Fowler, V. G., Perkins, B., … Bergin, S. P. (2026). Timing of Bronchoscopy and Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Host Pneumonia. Open Forum Infect Dis, 13(6), ofag361. https://doi.org/10.1093/ofid/ofag361
Mourad, Ahmad, Daniel S. Lupu, Morgan Richey, Paul Steven, Vance G. Fowler, Brad Perkins, Thomas L. Holland, and Stephen P. Bergin. “Timing of Bronchoscopy and Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Host Pneumonia.Open Forum Infect Dis 13, no. 6 (June 2026): ofag361. https://doi.org/10.1093/ofid/ofag361.
Mourad A, Lupu DS, Richey M, Steven P, Fowler VG, Perkins B, et al. Timing of Bronchoscopy and Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Host Pneumonia. Open Forum Infect Dis. 2026 Jun;13(6):ofag361.
Mourad, Ahmad, et al. “Timing of Bronchoscopy and Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Host Pneumonia.Open Forum Infect Dis, vol. 13, no. 6, June 2026, p. ofag361. Pubmed, doi:10.1093/ofid/ofag361.
Mourad A, Lupu DS, Richey M, Steven P, Fowler VG, Perkins B, Holland TL, Bergin SP. Timing of Bronchoscopy and Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Host Pneumonia. Open Forum Infect Dis. 2026 Jun;13(6):ofag361.
Journal cover image

Published In

Open Forum Infect Dis

DOI

ISSN

2328-8957

Publication Date

June 2026

Volume

13

Issue

6

Start / End Page

ofag361

Location

United States

Related Subject Headings

  • 3207 Medical microbiology
  • 3202 Clinical sciences